Plasma Elevations of Tumor Necrosis Factor-Receptor-1 at Day 7 Postallogeneic Transplant Correlate with Graft-versus-Host Disease Severity and Overall Survival in Pediatric Patients

Carrie L. Kitko, Sophie Paczesny, Gregory Yanik, Thomas Braun, Dawn Jones, Joel Whitfield, Sung W. Choi, Raymond J. Hutchinson, James L M Ferrara, John E. Levine

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Tumor necrosis factor-α (TNF-α) is known to play a role in the pathogenesis of graft-versus-host disease (GVHD), a cause of significant morbidity and treatment-related mortality (TRM) after allogeneic hematopoietic stem cell transplantation (HCT). We measured the concentration of TNF-Receptor-1 (TNFR1) in the plasma of HCT recipients as a surrogate marker for TNF-α both prior to transplant and at day 7 in 82 children who underwent a myeloablative allogeneic HCT at the University of Michigan between 2000 and 2005. GVHD grade II-IV developed in 39% of patients at a median of 20 days after HCT. Increases in TNFR1 level at day 7 post-HCT, expressed as ratios compared to pretransplant baseline, correlated with the severity of GVHD (P = .02). In addition, day 7 TNFR1 ratios >2.5 baseline were associated with inferior 1-year overall survival (OS 51% versus 74%, P = .04). As an individual biomarker, TNFR1 lacks sufficient precision to be used as a predictor for the development of GVHD. However, increases in the concentration of TNFR1, which are detectable up to 2 weeks in advance of clinical manifestations of GVHD, correlate with survival in pediatric HCT patients.

Original languageEnglish (US)
Pages (from-to)759-765
Number of pages7
JournalBiology of Blood and Marrow Transplantation
Volume14
Issue number7
DOIs
StatePublished - Jul 2008
Externally publishedYes

Fingerprint

Tumor Necrosis Factor Receptors
Hematopoietic Stem Cell Transplantation
Graft vs Host Disease
Pediatrics
Transplants
Survival
Tumor Necrosis Factor-alpha
Biomarkers
Morbidity
Mortality

Keywords

  • GVHD
  • Hematopoietic stem cell transplantation
  • Pediatrics
  • TNF

ASJC Scopus subject areas

  • Transplantation

Cite this

Plasma Elevations of Tumor Necrosis Factor-Receptor-1 at Day 7 Postallogeneic Transplant Correlate with Graft-versus-Host Disease Severity and Overall Survival in Pediatric Patients. / Kitko, Carrie L.; Paczesny, Sophie; Yanik, Gregory; Braun, Thomas; Jones, Dawn; Whitfield, Joel; Choi, Sung W.; Hutchinson, Raymond J.; Ferrara, James L M; Levine, John E.

In: Biology of Blood and Marrow Transplantation, Vol. 14, No. 7, 07.2008, p. 759-765.

Research output: Contribution to journalArticle

Kitko, Carrie L. ; Paczesny, Sophie ; Yanik, Gregory ; Braun, Thomas ; Jones, Dawn ; Whitfield, Joel ; Choi, Sung W. ; Hutchinson, Raymond J. ; Ferrara, James L M ; Levine, John E. / Plasma Elevations of Tumor Necrosis Factor-Receptor-1 at Day 7 Postallogeneic Transplant Correlate with Graft-versus-Host Disease Severity and Overall Survival in Pediatric Patients. In: Biology of Blood and Marrow Transplantation. 2008 ; Vol. 14, No. 7. pp. 759-765.
@article{03dc99efd02b401cb98a86a53bc34f73,
title = "Plasma Elevations of Tumor Necrosis Factor-Receptor-1 at Day 7 Postallogeneic Transplant Correlate with Graft-versus-Host Disease Severity and Overall Survival in Pediatric Patients",
abstract = "Tumor necrosis factor-α (TNF-α) is known to play a role in the pathogenesis of graft-versus-host disease (GVHD), a cause of significant morbidity and treatment-related mortality (TRM) after allogeneic hematopoietic stem cell transplantation (HCT). We measured the concentration of TNF-Receptor-1 (TNFR1) in the plasma of HCT recipients as a surrogate marker for TNF-α both prior to transplant and at day 7 in 82 children who underwent a myeloablative allogeneic HCT at the University of Michigan between 2000 and 2005. GVHD grade II-IV developed in 39{\%} of patients at a median of 20 days after HCT. Increases in TNFR1 level at day 7 post-HCT, expressed as ratios compared to pretransplant baseline, correlated with the severity of GVHD (P = .02). In addition, day 7 TNFR1 ratios >2.5 baseline were associated with inferior 1-year overall survival (OS 51{\%} versus 74{\%}, P = .04). As an individual biomarker, TNFR1 lacks sufficient precision to be used as a predictor for the development of GVHD. However, increases in the concentration of TNFR1, which are detectable up to 2 weeks in advance of clinical manifestations of GVHD, correlate with survival in pediatric HCT patients.",
keywords = "GVHD, Hematopoietic stem cell transplantation, Pediatrics, TNF",
author = "Kitko, {Carrie L.} and Sophie Paczesny and Gregory Yanik and Thomas Braun and Dawn Jones and Joel Whitfield and Choi, {Sung W.} and Hutchinson, {Raymond J.} and Ferrara, {James L M} and Levine, {John E.}",
year = "2008",
month = "7",
doi = "10.1016/j.bbmt.2008.04.002",
language = "English (US)",
volume = "14",
pages = "759--765",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "7",

}

TY - JOUR

T1 - Plasma Elevations of Tumor Necrosis Factor-Receptor-1 at Day 7 Postallogeneic Transplant Correlate with Graft-versus-Host Disease Severity and Overall Survival in Pediatric Patients

AU - Kitko, Carrie L.

AU - Paczesny, Sophie

AU - Yanik, Gregory

AU - Braun, Thomas

AU - Jones, Dawn

AU - Whitfield, Joel

AU - Choi, Sung W.

AU - Hutchinson, Raymond J.

AU - Ferrara, James L M

AU - Levine, John E.

PY - 2008/7

Y1 - 2008/7

N2 - Tumor necrosis factor-α (TNF-α) is known to play a role in the pathogenesis of graft-versus-host disease (GVHD), a cause of significant morbidity and treatment-related mortality (TRM) after allogeneic hematopoietic stem cell transplantation (HCT). We measured the concentration of TNF-Receptor-1 (TNFR1) in the plasma of HCT recipients as a surrogate marker for TNF-α both prior to transplant and at day 7 in 82 children who underwent a myeloablative allogeneic HCT at the University of Michigan between 2000 and 2005. GVHD grade II-IV developed in 39% of patients at a median of 20 days after HCT. Increases in TNFR1 level at day 7 post-HCT, expressed as ratios compared to pretransplant baseline, correlated with the severity of GVHD (P = .02). In addition, day 7 TNFR1 ratios >2.5 baseline were associated with inferior 1-year overall survival (OS 51% versus 74%, P = .04). As an individual biomarker, TNFR1 lacks sufficient precision to be used as a predictor for the development of GVHD. However, increases in the concentration of TNFR1, which are detectable up to 2 weeks in advance of clinical manifestations of GVHD, correlate with survival in pediatric HCT patients.

AB - Tumor necrosis factor-α (TNF-α) is known to play a role in the pathogenesis of graft-versus-host disease (GVHD), a cause of significant morbidity and treatment-related mortality (TRM) after allogeneic hematopoietic stem cell transplantation (HCT). We measured the concentration of TNF-Receptor-1 (TNFR1) in the plasma of HCT recipients as a surrogate marker for TNF-α both prior to transplant and at day 7 in 82 children who underwent a myeloablative allogeneic HCT at the University of Michigan between 2000 and 2005. GVHD grade II-IV developed in 39% of patients at a median of 20 days after HCT. Increases in TNFR1 level at day 7 post-HCT, expressed as ratios compared to pretransplant baseline, correlated with the severity of GVHD (P = .02). In addition, day 7 TNFR1 ratios >2.5 baseline were associated with inferior 1-year overall survival (OS 51% versus 74%, P = .04). As an individual biomarker, TNFR1 lacks sufficient precision to be used as a predictor for the development of GVHD. However, increases in the concentration of TNFR1, which are detectable up to 2 weeks in advance of clinical manifestations of GVHD, correlate with survival in pediatric HCT patients.

KW - GVHD

KW - Hematopoietic stem cell transplantation

KW - Pediatrics

KW - TNF

UR - http://www.scopus.com/inward/record.url?scp=44649181014&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44649181014&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2008.04.002

DO - 10.1016/j.bbmt.2008.04.002

M3 - Article

VL - 14

SP - 759

EP - 765

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 7

ER -